Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase domain 32 (ADAM32) is a member of the disintegrin and metalloproteinase (ADAM) family, which consists of membrane-anchored proteins involved in diverse physiological processes including cell adhesion, migration, and signaling[1][2][3]. ADAM32 is predominantly expressed in the testis and may play a specialized role in sperm development and fertilization[1][4]. Unlike many family members, ADAM32 is considered non-catalytic (lacking proteolytic activity), meaning it primarily mediates protein–protein interactions rather than functioning as an active sheddase or protease[4]. Its gene is located on human chromosome 8 and undergoes alternative splicing to produce several isoforms[1]. While other ADAM family members are implicated in cancer, inflammation, and other diseases, there is currently no direct evidence linking ADAM32 to specific human pathologies, nor are there any approved drugs that directly target it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase domain 32 (ADAM32).